Protein degradation rapidly inactivates protein function and is used in many biological contexts to trigger irreversible transitions. The major protein degradation pathway, the ubiquitin proteasome system (UPS), includes hundreds of E3 ubiquitin ligases that attach ubiquitin to thousands of substrates, targeting them for proteolytic cleavage by the 26S proteasome. We are interested in how E3 ubiquitin ligases recognize their substrates (Scrima et al., Cell, 2008), and how small molecule compounds such as thalidomide (also known as Contergan or Softenon) divert ligase function to induce degradation of disease-related proteins (Fischer et al., Nature, 2014; Petzold et al., Nature, 2016; Sievers et al., Science, 2018; Slabicki et al., Nature 2020; Kozicka et al., Nat. Chem. Biol. 2024).
The Thomä Lab is particularly interested in the degradation of transcription factors, such as the nuclear hormone receptors (NHRs), which are crucial for gene regulation through ligand binding (Tsai et al., Mol. Cell 2023). Medicines targeting NHRs, used in clinical settings for conditions like inflammation and cancers, exploit their druggable nature. We aim to find endogenous and drug-induced mechanisms of transcription factor degradation and investigate how small molecule molecular glues rewire the interactome of proteins. Our approach combines biophysical, biochemical, and structural biology methods, including mass spectroscopy, mass photometry, next-gen sequencing, genetic screens and cryo-EM, to illuminate the intricacies of targeted protein degradation, and to study the rewiring of protein-protein interactions through small molecules (molecular glues).